Who is sponsoring NCT02178722?

NCT02178722 is sponsored by Incyte Corporation.

What drugs are being tested in NCT02178722?

Interventions in NCT02178722: MK-3475, INCB024360.

What condition does NCT02178722 study?

NCT02178722 studies Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC).

Is NCT02178722 still recruiting?

NCT02178722 is currently completed. Last updated 14 February 2022.

Are results published for NCT02178722?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-02-14 · How we verify

NCT02178722

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Completed Phase 1, PHASE2 Results posted Last updated 14 February 2022

What this trial tests

Phase 1, PHASE2 trial testing MK-3475 in Microsatellite-instability (MSI) High Colorectal Cancer (CRC) in 444 participants. Completed in 6 November 2020.

Timeline

17 July 2014

Primary endpoint
26 November 2018

6 November 2020

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	444
Start date	17 July 2014
Primary completion	26 November 2018
Estimated completion	6 November 2020
Sites	24 locations across United States

Drugs / interventions tested

MK-3475 — full drug profile →
INCB024360 — full drug profile →

Conditions studied

Microsatellite-instability (MSI) High Colorectal Cancer (CRC) — all drugs for Microsatellite-instability (MSI) High Colorectal Cancer (CRC) →
Endometrial Cancer — all drugs for Endometrial Cancer →
Head and Neck Cancer — all drugs for Head and Neck Cancer →
Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with Microsatellite-instability (MSI) High Colorectal Cancer (CRC) or Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events Primary · Approximately 54 months

An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occur after a participant provides informed consent. A TEAE is any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug. Serious adverse event (SAE) is defined as an event that meets 1 of the following criteria: is fatal or life threatening, results in persistent or significant disability or incapacity, constitutes a congenital anomaly or birth defect, is clinically meaningful (i.e. defi

SAE

Group	Value	95% CI
Phase 1: Epacadostat 25 mg BID	0
Phase 1: Epacadostat 50 mg BID	40.0
Phase 1: Epacadostat 100 mg BID	50.0
Phase 1: Epacadostat 300 mg BID	45.0

TEAS

Group	Value	95% CI
Phase 1: Epacadostat 25 mg BID	100.
Phase 1: Epacadostat 50 mg BID	95.0
Phase 1: Epacadostat 100 mg BID	94.4
Phase 1: Epacadostat 300 mg BID	100.

Phase 2: Objective Response Rate (ORR) Primary · Approximately 54 months

ORR was percentage of participants with best overall response \[complete response (CR) or partial response (PR)\], per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Triple negative breast cancer

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	11.1

Microsatellite-instability high colorectal cancer

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	43.8

Gastric cancer

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	22.2

Hepatocellular carcinoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	16.7

Melanoma - immune checkpoint-naïve

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	60.5

Non-small cell lung cancer (NSCLC) (tumor proportion score (TPS) < 50% or indeterminate)

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	30.8

NSCLC programmed cell death ligand (PD-L1) low negative (TPS < 50%)

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	24.4

Ovarian cancer

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	8.1

Phase 2: Duration of Response (DOR) Secondary · Up to 54 months

Duration of response is the time from the first overall response contributing to an objective response (complete or partial response) for DLBCL to the date of death or the date of first overall response of progressive diseasemeasured (by irRECIST for solid tumors or the Lugano Classification, whichever is earliest.

Hepatocellular Carcinoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	NA	2.04 – NA

Triple Negative Breast Cancer

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	NA	0.92 – NA

Immune Checkpoint-naïve Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	NA	26.35 – NA

NSCLC high positive (PD-L1 TPS ≥ 50%)

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	12.44	2.10 – 16.53

NSCLC low/negative or indeterminate (PD-L1 TPS < 50% or indeterminate)

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	11.93	8.90 – 14.95

NSCLC (TPS 0%)

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	NA	7.43 – NA

NSCLC Unknown

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	10.84	4.14 – NA

Renal Cell Carcinoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	16.95	12.58 – NA

Phase 2: Progression Free Survival (PFS) Secondary · Up to 54 months

Progression-free survival is defined as number of days from the first day of taking study drug to the earlier of death or disease progression by irRECIST v1.1 for select solid tumors and modified Lugano Classification for DLBCL.

Hepatocellular Carcinoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	5.49	2.69 – 10.28

Triple Negative Breast Cancer

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	1.97	1.87 – 2.92

Immune Checkpoint-naïve Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	16.69	6.24 – NA

Primary Refractory Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	1.69	1.25 – 2.14

Relapsed Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	2.60	2.14 – 4.21

NSCLC

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	4.09	2.14 – 7.36

Renal Cell Carcinoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	4.50	2.33 – 6.24

Squamous Cell Carcinoma of the Head and Neck

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	4.37	2.30 – 7.79

Phase 2: Duration of Disease Control Secondary · Up to 54 months

The duration of disease control is the time from the treatment start date to the first objective response of PD (by irRECIST v1.1 or Lugano Classification), death, or last tumor assessment date (if PD/death not present), for subjects with best overall response of SD or better.

Hepatocellular Carcinoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	10.38	5.49 – NA

Triple Negative Breast Cancer

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	11.47	4.01 – 12.65

Immune Checkpoint-naïve Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	30.29	25.03 – NA

Relapsed Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	4.21	NA – NA

NSCLC Total

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	14.42	8.51 – 19.45

Renal Cell Carcinoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	13.39	5.13 – 18.86

Squamous Cell Carcinoma of the Head and Neck

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	9.18	6.24 – 13.34

Transitional Cell Carcinoma of the GU Tract

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	15.36	8.41 – 22.74

Phase 2: Overall Survival (OS) Secondary · Up to 54 months

Overall survival is determined from the date of first dose until death due to any cause.

Hepatocellular Carcinoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	NA	8.94 – NA

Triple Negative Breast Cancer

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	5.16	4.60 – 7.46

Immune Checkpoint-naïve Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	NA	NA – NA

Primary Refractory Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	NA	NA – NA

Relapsed Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	NA	2.60 – NA

NSCLC

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	14.62	9.72 – 24.38

Renal Cell Carcinoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	NA	18.40 – NA

Squamous Cell Carcinoma of the Head and Neck

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	8.34	4.37 – 15.41

Phase 2: Ordinal Categorical Response Score Secondary · Up to 54 months

Ordinal categorical response score, determined by radiographic disease assessments per irRECIST v1.1. The 5-category ordinal response endpoint is determined at a given timepoint by classifying response into one of the following groups: 1 = Complete response per irRECIST v1.1 2 = Very good response, defined as \> 60% tumor reduction 3 = Minor response, defined as \> 30% to ≤ 60% tumor reduction 4 = Stable disease per irRECIST v1.1 5 = Progressive disease per irRECIST v1.1

Hepatocellular Carcinoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	0
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	2
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	2
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	11

Triple Negative Breast Cancer

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	1
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	1
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	2
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	7

Immune Checkpoint-naïve Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	3
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	17
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	6
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	5

Primary Refractory Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	0
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	0
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	0
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	0

Relapsed Melanoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	3
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	4
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	5
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	8

NSCLC

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	4
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	3
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	8
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	15

Renal Cell Carcinoma

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	2
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	6
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	4
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	10

Squamous Cell Carcinoma of the Head and Neck

Group	Value	95% CI
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	3
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	4
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	5
Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W	8

Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events Secondary · Up to 54 months

Treatment-Emergent Adverse Events (TEAE)

Group	Value	95% CI
Phase 2: Epacadostat 100 mg BID	100

Serious Treatment-Emergent Adverse Events

Group	Value	95% CI
Phase 2: Epacadostat 100 mg BID	51.0

Adverse events — posted to ClinicalTrials.gov

Time frame: Approximately 54 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Phase 1: Epacadostat 25 mg BID

Serious: 0/4 (0%)

Deaths: 2/4

Phase 1: Epacadostat 50 MG BID

Serious: 8/20 (40%)

Deaths: 13/20

Phase 1: Epacadostat 100 MG BID

Serious: 9/18 (50%)

Deaths: 12/18

Phase 1: Epacadostat 300 MG BID

Serious: 9/20 (45%)

Deaths: 14/20

Phase 2: Epacadostat 100 MG BID

Serious: 195/382 (51%)

Deaths: 209/382

Total

Serious: 221/444 (50%)

Deaths: 250/444

Serious adverse events (198 terms)

Reaction	System	Phase 1: Epacadostat 25 mg…	Phase 1: Epacadostat 50 MG…	Phase 1: Epacadostat 100 M…	Phase 1: Epacadostat 300 M…	Phase 2: Epacadostat 100 M…	Total
Malignant neoplasm progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Pleural effusion	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—
Disease progression	General disorders	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—	—	—	—
Colitis	Gastrointestinal disorders	—	—	—	—	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—
Hypotension	Vascular disorders	—	—	—	—	—	—
Pericardial effusion	Cardiac disorders	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—
Acute respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—
Failure to thrive	Metabolism and nutrition disorders	—	—	—	—	—	—
Pneumonia aspiration	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Pneumonitis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—

Other adverse events (280 terms — click to expand)

Reaction	System	Phase 1: Epacadostat 25 mg…	Phase 1: Epacadostat 50 MG…	Phase 1: Epacadostat 100 M…	Phase 1: Epacadostat 300 M…	Phase 2: Epacadostat 100 M…	Total
Fatigue	General disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—
Lipase increased	Investigations	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—
Amylase increased	Investigations	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—	—	—
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—
Hypothyroidism	Endocrine disorders	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—
Anxiety	Psychiatric disorders	—	—	—	—	—	—
Productive cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—

Most-reported serious reactions: Malignant neoplasm progression, Pneumonia, Abdominal pain, Nausea, Pleural effusion, Dyspnoea, Small intestinal obstruction, Disease progression.

Data from ClinicalTrials.gov NCT02178722 adverse events section.

Sponsor's own description

The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular therapies and precision medicine for hepatocellular carcinoma.
Llovet JM, Montal R, Sia D, Finn RS. · · 2018 · cited 1481× · PMID 30061739 · DOI 10.1038/s41571-018-0073-4
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.
Munn DH, Mellor AL. · · 2016 · cited 799× · PMID 26839260 · DOI 10.1016/j.it.2016.01.002
Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, et al · · 2018 · cited 582× · PMID 29544515 · DOI 10.1186/s13045-018-0582-8
Targeting the IDO1 pathway in cancer: from bench to bedside.
Liu M, Wang X, Wang L, Ma X, et al · · 2018 · cited 339× · PMID 30068361 · DOI 10.1186/s13045-018-0644-y
IDO1 in cancer: a Gemini of immune checkpoints.
Zhai L, Ladomersky E, Lenzen A, Nguyen B, et al · · 2018 · cited 319× · PMID 29375124 · DOI 10.1038/cmi.2017.143
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).
Mitchell TC, Hamid O, Smith DC, Bauer TM, et al · · 2018 · cited 307× · PMID 30265610 · DOI 10.1200/jco.2018.78.9602
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Zhai L, Spranger S, Binder DC, Gritsina G, et al · · 2015 · cited 262× · PMID 26519060 · DOI 10.1158/1078-0432.ccr-15-0420
Targeting the indoleamine 2,3-dioxygenase pathway in cancer.
Moon YW, Hajjar J, Hwu P, Naing A. · · 2015 · cited 255× · PMID 26674411 · DOI 10.1186/s40425-015-0094-9

Verify or expand the search:

Other trials of MK-3475

Trials testing the same drug.

NCT05879653 — Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD) · Phase 2 · recruiting
NCT05832827 — First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Art · Phase 2 · recruiting
NCT04098068 — Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) · Phase 2 · completed
NCT03003468 — Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten C · Phase 1, PHASE2 · completed
NCT02852655 — A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembr · Phase 1 · active not recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02178722 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 14 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02178722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02178722

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (198 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of MK-3475

Other Incyte Corporation trials

Verify against primary sources